Sensei Biotherapeutics (NASDAQ:SNSE) Announces Earnings Results, Misses Expectations By $130.83 EPS

Sensei Biotherapeutics (NASDAQ:SNSE) posted its earnings results on Friday. The company reported ($131.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83), FiscalAI reports.

Sensei Biotherapeutics Stock Up 3.1%

Shares of SNSE opened at $20.43 on Friday. The stock has a market capitalization of $27.38 million, a P/E ratio of -0.14 and a beta of -0.18. Sensei Biotherapeutics has a twelve month low of $5.25 and a twelve month high of $36.76. The company has a 50 day moving average of $28.89 and a 200-day moving average of $17.87.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Leerink Partners assumed coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They set an “outperform” rating and a $50.00 target price for the company. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Finally, Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Sensei Biotherapeutics presently has an average rating of “Hold” and a consensus price target of $40.00.

Sensei Biotherapeutics News Summary

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Insider Buying and Selling at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, major shareholder Millennium Management Llc purchased 15,321 shares of the firm’s stock in a transaction dated Friday, March 27th. The stock was bought at an average cost of $26.61 per share, with a total value of $407,691.81. Following the purchase, the insider directly owned 142,360 shares of the company’s stock, valued at $3,788,199.60. The trade was a 12.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders have purchased 46,980 shares of company stock worth $1,341,669 and have sold 23,067 shares worth $704,439. 23.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.